{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:41:06Z","timestamp":1792251666927,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008454","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,11,9]],"date-time":"2011-11-09T00:00:00Z","timestamp":1320796800000}}],"reference-count":55,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008454.pub2","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T14:19:23Z","timestamp":1320157163000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies"],"prefix":"10.1002","volume":"2011","author":[{"given":"Karen","family":"Rees","sequence":"first","affiliation":[{"name":"Warwick Medical School, University of Warwick; Division of Health Sciences; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Stowe","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitaa","family":"Patel","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ives","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Breen","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Society; Research and Development Directorate; 215 Vauxhall Bridge Road London UK SW1V 1EJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E","family":"Clarke","sequence":"additional","affiliation":[{"name":"College of Medicine and Dental Sciences; School of Clinical and Experimental Medicine; University of Birmingham Edgbaston Birmingham West Midlands UK B18 7QH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[{"name":"Canynge Hall; Dept of Social Medicine; Whiteladies Road Bristol UK BS8 2PR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,9]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD008454.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000108110","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease","volume":"28","author":"Bornebroek","year":"2007","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1002\/14651858.CD008454.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/01.wnl.0000227906.99570.cc","article-title":"Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study","volume":"67","author":"Bower-JH","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD008454.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease","volume":"60","author":"Chen","year":"2003","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008454.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20682","article-title":"Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease","volume":"58","author":"Chen","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"d198","DOI":"10.1136\/bmj.d198","article-title":"Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case control study","volume":"342","author":"Driver","year":"2011","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"d198","DOI":"10.1136\/bmj.d198","article-title":"Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case control study","volume":"342","author":"Driver","year":"2011","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD008454.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/157488606777934404","article-title":"NSAID use and the risk of Parkinson's disease","volume":"1","author":"Etminan","year":"2006","journal-title":"Current Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD008454.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jocn.2007.02.095","article-title":"Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study","volume":"15","author":"Etminan","year":"2008","journal-title":"Journal of Clinical Neuroscience"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1212\/WNL.0b013e31820f2d79","article-title":"Use of ibuprofen and risk of Parkinson disease","volume":"76","author":"Gao","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008454.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/archneur.64.4.576","article-title":"Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease","volume":"64","author":"Hancock","year":"2007","journal-title":"Archives of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD008454.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1212\/01.wnl.0000204446.82823.28","article-title":"Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease","volume":"66","author":"Hernan","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008454.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/mds.21782","article-title":"Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk","volume":"23","author":"Powers","year":"2008","journal-title":"Movement Disorders"},{"issue":"7","key":"10.1002\/14651858.CD008454.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.20856","article-title":"Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease","volume":"21","author":"Ton","year":"2006","journal-title":"Movement Disorders"},{"issue":"19","key":"10.1002\/14651858.CD008454.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1212\/01.wnl.0000279519.99344.ad","article-title":"Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease","volume":"69","author":"Wahner","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/WNL.34.3.400","article-title":"Diflunisal in idiopathic Parkinson's disease","volume":"34","author":"Anderson","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0016|cit16","unstructured":"Bartels AL Leenders K Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease mRCT register ISRCTN 59798735 2007"},{"issue":"1","key":"10.1002\/14651858.CD008454.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/aje\/kwm260","article-title":"Peripheral inflammatory biomarkers and risk of Parkinson's disease","volume":"167","author":"Chen","year":"2008","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.b.30449","article-title":"Cycloxygenase-2 polymorphisms in Parkinson's disease","volume":"144B","author":"Hakansson","year":"2007","journal-title":"American Journal of Medical Genetics Part B (Neuropsychiatric Genetics)"},{"issue":"14","key":"10.1002\/14651858.CD008454.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/mds.23274","article-title":"Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study","volume":"25","author":"Rugbjerg","year":"2010","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneur.64.6.836","article-title":"Inflammatory cytokine gene polymorphisms and increased risk of Parkinson's disease","volume":"64","author":"Wahner","year":"2007","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1474-4422(07)70293-4","article-title":"Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial","volume":"7","author":"AD2000 Collaborative Group","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial","volume":"68","author":"ADAPT Research Group","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD008454.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","article-title":"Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)","volume":"65","author":"ADAPT Research Group","year":"2008","journal-title":"Archives of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD008454.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1371\/journal.pctr.0010033","article-title":"Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)","volume":"1","author":"ADAPT research group","year":"2006","journal-title":"PLoS Clinical Trials"},{"issue":"7","key":"10.1002\/14651858.CD008454.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1212\/WNL.58.7.1050","article-title":"Randomized pilot study of nimesulide treatment in Alzheimer's disease","volume":"58","author":"Aisen","year":"2002","journal-title":"Neurology"},{"issue":"21","key":"10.1002\/14651858.CD008454.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD008454.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2007.05.006","article-title":"Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?","volume":"206","author":"Asanuma","year":"2007","journal-title":"Experimental Neurology"},{"issue":"14","key":"10.1002\/14651858.CD008454.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2174\/138161208784480153","article-title":"Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease","volume":"14","author":"Asanuma","year":"2008","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1212\/WNL.0b013e3181a18691","article-title":"Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort","volume":"72","author":"Breitner","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Reeves BC Deeks JJ Higgins JPT Wells GA Chapter 13: Including non-randomised studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org.","DOI":"10.1002\/9780470712184.ch13"},{"issue":"1","key":"10.1002\/14651858.CD008454.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006378","article-title":"Aspirin and anti-inflammatory drugs for Alzheimer's disease","author":"Davis","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008454.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/aje\/kwi029","article-title":"Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia","volume":"161","author":"de-Craen","year":"2005","journal-title":"American Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD008454.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.expneurol.2007.02.008","article-title":"Non-steroidal anti-inflammatory drugs in Parkinson's disease","volume":"205","author":"Esposito","year":"2007","journal-title":"Experimental Neurology"},{"issue":"7407","key":"10.1002\/14651858.CD008454.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","article-title":"Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies","volume":"327","author":"Etminan","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson's disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008454.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WCO.0b013e3280adc943","article-title":"Therapeutic approaches to inflammation in neurodegenerative disease","volume":"20","author":"Klegeris","year":"2007","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0091270005278202","article-title":"The cardiovascular toxicity of selective and nonselective cycloxygenase inhibitors: comparisons, contrasts and aspirin confounding","volume":"45","author":"Konstantinopoulos","year":"2005","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.21751","article-title":"Glial reactions in Parkinson's disease","volume":"23","author":"McGeer","year":"2008","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD008454.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0041|cit41","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjmed.2005.10.056","article-title":"Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs","volume":"119","author":"Salpeter","year":"2006","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.410170124","article-title":"Acute exacerbation of Parkinson's disease with sulindac","volume":"17","author":"Sandyk","year":"1985","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008454.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer's disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"issue":"7002","key":"10.1002\/14651858.CD008454.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.311.7002.422b","article-title":"Exacerbation of idiopathic Parkinson's disease by naproxen","volume":"311","author":"Shaunak","year":"1995","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD008454.pub2-BIB0046|cit46","first-page":"478","article-title":"Inflammation in Parkinson's disease: an update","volume":"9","author":"Smith","year":"2008","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"4","key":"10.1002\/14651858.CD008454.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000078501","article-title":"Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review","volume":"23","author":"Szekely","year":"2004","journal-title":"Neuroepidemiology"},{"issue":"24","key":"10.1002\/14651858.CD008454.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/01.wnl.0000313933.17796.f6","article-title":"No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies","volume":"70","author":"Szekely","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008454.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003673","article-title":"Indomethacin for Alzheimer's disease","author":"Tabet","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008454.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004031","article-title":"Ibuprofen for Alzheimer's disease","author":"Tabet","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008454.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ije\/dym296","article-title":"What is the harm-benefit ratio of Cox-2 inhibitors?","volume":"37","author":"Staa","year":"2008","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0053|cit53","unstructured":"Wells GA Shea B O'Connell D Peterson J Welch V Losos M The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Available from: www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm 2008"},{"key":"10.1002\/14651858.CD008454.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/092986706776055760","article-title":"An inflammatory pathomechanism for Parkinson's disease?","volume":"13","author":"Wersinger","year":"2006","journal-title":"Current Medicinal Chemistry"},{"issue":"8","key":"10.1002\/14651858.CD008454.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","article-title":"Inflammation as a causative factor in the aetiology of Parkinson's disease","volume":"150","author":"Whitton","year":"2007","journal-title":"British Journal of Pharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008454.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:31:55Z","timestamp":1789551115000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008454.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,11,9]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008454.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,9]]}}}